Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia

Andrea Henrich, Markus Joerger, Stefanie Kraff, Ulrich Jaehde, Wilhelm Huisinga, Charlotte Kloft and Zinnia Patricia Parra-Guillen
Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 347-358; DOI: https://doi.org/10.1124/jpet.117.240309
Andrea Henrich
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Joerger
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefanie Kraff
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Jaehde
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilhelm Huisinga
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Kloft
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zinnia Patricia Parra-Guillen
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Visual Overview

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Paclitaxel is a commonly used cytotoxic anticancer drug with potentially life-threatening toxicity at therapeutic doses and high interindividual pharmacokinetic variability. Thus, drug and effect monitoring is indicated to control dose-limiting neutropenia. Joerger et al. (2016) developed a dose individualization algorithm based on a pharmacokinetic (PK)/pharmacodynamic (PD) model describing paclitaxel and neutrophil concentrations. Furthermore, the algorithm was prospectively compared in a clinical trial against standard dosing (Central European Society for Anticancer Drug Research Study of Paclitaxel Therapeutic Drug Monitoring; 365 patients, 720 cycles) but did not substantially improve neutropenia. This might be caused by misspecifications in the PK/PD model underlying the algorithm, especially without consideration of the observed cumulative pattern of neutropenia or the platinum-based combination therapy, both impacting neutropenia. This work aimed to externally evaluate the original PK/PD model for potential misspecifications and to refine the PK/PD model while considering the cumulative neutropenia pattern and the combination therapy. An underprediction was observed for the PK (658 samples), the PK parameters, and these parameters were re-estimated using the original estimates as prior information. Neutrophil concentrations (3274 samples) were overpredicted by the PK/PD model, especially for later treatment cycles when the cumulative pattern aggravated neutropenia. Three different modeling approaches (two from the literature and one newly developed) were investigated. The newly developed model, which implemented the bone marrow hypothesis semiphysiologically, was superior. This model further included an additive effect for toxicity of carboplatin combination therapy. Overall, a physiologically plausible PK/PD model was developed that can be used for dose adaptation simulations and prospective studies to further improve paclitaxel/carboplatin combination therapy.

Footnotes

    • Received February 28, 2017.
    • Accepted June 5, 2017.
  • C.K. and W.H. are supported by grants from an industry consortium comprising AbbVie Deutschland GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal GmbH, F. Hoffmann-La Roche Ltd., Merck KGaA, and Sanofi. C.K. is supported by grants from the Innovative Medicines Initiative Joint Undertaking (DDMoRe: Drug Disease Modelling Resources) and Diurnal Ltd.

  • C.K. and Z.P.P.-G. are co-senior authors.

  • Part of this work was previously presented at the following meetings:

    Henrich A, Joerger M, Huisinga W, Kloft C, and Parra-Guillen ZP (2015) External evaluation of a PK/PD model describing the time course of paclitaxel and neutropenia in patients with advanced non-small cell lung cancer. 24th Population Approach Group Europe (PAGE); 2015 Jun 02-05; Hersonissos, Greece.

  • Henrich A, Joerger M, Huisinga W, Kloft C, and Parra-Guillen ZP (2015) Dose-individualisation of paclitaxel in patients with advanced non-small cell lung cancer: exploiting modelling and simulation to refine dosing algorithm. Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR); 2015 Sep 17-19; Innsbruck, Austria.

  • ↵Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga H, Kloft C, and Parra-Guillen ZP (2016) PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model. 25th Population Approach Group Europe (PAGE); 2016 Jun 07-10; Lisbon, Portugal. PAGE 25: 5879 [www.page-meeting.org/?abstract=5879], (2016).

  • Henrich A, Joerger M, Huisinga W, Parra-Guillen ZP, and Kloft C (2016) Semi-mechanistic PK/PD modelling to characterise long-term deterioration of neutropenia in cancer patients. Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR); 2016 Sep 08-10; Munich, Germany.

  • Henrich A, Joerger M, Huisinga W, Kloft C, and Parra-Guillen ZP (2016) Characterisation of bone marrow exhaustion and long-term neutropenia by applying PK/PD modelling. Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG); 2016 Oct 04-07; Munich, Germany.

  • https://doi.org/10.1124/jpet.117.240309.

  • Embedded ImageThis article has supplemental material available at jpet.aspetjournals.org.

  • Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 362 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 362, Issue 2
1 Aug 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

Bone Marrow Exhaustion PK/PD Model for Cumulative Neutropenia

Andrea Henrich, Markus Joerger, Stefanie Kraff, Ulrich Jaehde, Wilhelm Huisinga, Charlotte Kloft and Zinnia Patricia Parra-Guillen
Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 347-358; DOI: https://doi.org/10.1124/jpet.117.240309

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

Bone Marrow Exhaustion PK/PD Model for Cumulative Neutropenia

Andrea Henrich, Markus Joerger, Stefanie Kraff, Ulrich Jaehde, Wilhelm Huisinga, Charlotte Kloft and Zinnia Patricia Parra-Guillen
Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 347-358; DOI: https://doi.org/10.1124/jpet.117.240309
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Targeting LGR5-Positive Cells in Ovarian Cancer
  • Ocular Palonosetron for Prevention of Nausea and Vomiting
  • PTP4A3 and Ovarian Cancer
Show more Chemotherapy, Antibiotics, and Gene Therapy

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics